New Science Ventures

What New Science Ventures does

New Science Ventures, LLC (NSV) is a Greenwich, Connecticut-based venture capital firm founded in 2004 that also maintains a London office at Michelin House on Fulham Road. The firm invests in early- and late-stage companies using novel scientific approaches in the Life Sciences and Information Technology sectors, targeting businesses addressing large global markets (>$1B) with differentiated, IP-protected value propositions. NSV explicitly seeks contrarian opportunities outside traditional tech and life science hubs and employs virtual business models, building portfolio-company teams tailored to each stage of development. As of the input data, NSV manages over $900 million in assets under management based on original committed capital, deployed across a portfolio that includes Antevia Networks, Paragraf, Glydways, PlanetiQ, Pakal Technologies, biomodal, VORAGO Technologies, NorthSea Therapeutics, Novadip, Resolve Therapeutics, Zeotap, and others across US and European markets.

The firm operates with a small senior team led by Managing Partner Somu Subramaniam, with Partners Tom Lavin, Jean-Pierre Bizet (Partner & Senior Advisor), Andrew Abrams, and Partner/CFO Brenda Marex, supported by Controller Matt Crotty. NSV's revenue model follows standard venture capital mechanics: management fees on committed or invested capital plus carried interest on successful realizations, with no product pricing or subscription revenue. Deal flow is sourced through partner networks, syndicate relationships, and direct outreach to scientific founders, with NSV taking lead, follow-on, or sole-investor positions. Recent portfolio-company activity — including Glydways' $170M Series C in 2026, PlanetiQ's $15M U.S. Air Force STRATFI contract, and Paragraf's graphene-based quantum collaboration with Archer Materials — indicates the portfolio is reaching value-inflection milestones consistent with NSV's stated thesis of patient capital through scientific development cycles.

NSV's core "product" is capital allocation judgment grounded in deep scientific and sector expertise; the firm does not develop proprietary technology itself but curates exposure to science-based innovation. Its competitive position rests on partner experience (e.g., CFO Marex previously oversaw funds with over $8B AUM at Cerberus Capital; Partner Abrams' Cambridge/Harvard/J.P. Morgan background), transatlantic reach, and a contrarian sourcing strategy that produces differentiated deal flow. Active operational signals include a January 2025 lead investment in Pakal Technologies' $25M Series B and the October 2025 hire of a dedicated Controller, suggesting ongoing deployment and modest operational scaling.

Name

New Science Ventures

Legal name

New Science Ventures, LLC

Website

https://newscienceventures.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

1–10 employees

Short description

New Science Ventures is a Greenwich and London-based venture capital firm founded in 2004 that invests in early- and late-stage life sciences and information technology companies using novel scientific approaches, managing over $900 million in assets across US and European markets.

Ownership category

akta.pro rank

Headquarters

HQ city

Greenwich

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Investment Management: NSV generates returns through equity investments in early and late stage companies in life sciences and IT sectors. The firm manages over $900 million in assets under management based on original committed capital.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

New Science Ventures (NSV) is a Connecticut and London-based venture capital firm that invests in early and late stage companies using novel scientific approaches in the Life Sciences and Information Technology sectors. The firm deploys capital, board expertise, and active support to portfolio companies addressing significant unmet needs in global markets exceeding $1 billion, with over $900 million in assets under management. NSV takes a contrarian approach, focuses on science-based innovation with strong IP protection, employs virtual business models, and remains patient through value inflection points.

Product overview

New Science Ventures is a venture capital firm that does not offer products or services in the traditional sense. It invests in portfolio companies developing novel scientific technologies across Life Sciences and Information Technology sectors, including high-performance semiconductors, cellular infrastructure, data analytics/AI, IoT, therapeutics, and medical devices.

Differentiator

Problem solved

Functional benefit

Products and services

• Venture Capital Investment (Life Sciences and Information Technology) Equity capital investment in early and late stage companies using novel scientific approaches in Life Sciences and Information Technology sectors. NSV deploys capital, board expertise, and active support to portfolio companies addressing significant unmet needs in global markets exceeding $1 billion. The firm takes positions as lead, follow, or sole investor depending on the opportunity.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• ARCH Venture Partners: ARCH is a science-focused venture capital firm investing in early-stage life sciences and deep technology companies. It is highly comparable to NSV in its dual-thesis approach and focus on breakthrough, IP-protected innovation.
• Lux Capital: Lux Capital invests in science and technology ventures at the intersection of life sciences, deep tech, and frontier computing. Its thesis of supporting contrarian, science-driven founders closely mirrors NSV's positioning.
• Flagship Pioneering: Flagship Pioneering is a science-based venture firm that creates and invests in life sciences companies built around breakthrough platform technologies. Its focus on novel scientific approaches in life sciences directly parallels NSV's life sciences thesis.
• Atlas Venture: Atlas Venture is an early-stage life sciences-focused venture capital firm that builds and invests in biotechnology companies. It is comparable to NSV in its sector-specialized, early-stage life sciences focus.
• OrbiMed: OrbiMed is a healthcare-dedicated investment firm across venture, growth, and public equity. Its healthcare/life sciences focus and stage-flexibility make it directly comparable to NSV's life sciences investment activity.
• Khosla Ventures: Khosla Ventures invests across technology and life sciences, with a focus on bold, science-driven ventures. Its dual-sector focus and willingness to back contrarian, high-risk science-based ideas aligns closely with NSV's approach.
• MPM Capital: MPM Capital is a life sciences-focused venture firm investing in early- and late-stage therapeutics companies. Its specialization in life sciences at multiple stages is directly comparable to NSV's life sciences portfolio strategy.
• Versant Ventures: Versant Ventures is a healthcare-focused venture capital firm investing in biotechnology, medical devices, and healthcare services. Its stage-flexible, life sciences-focused model is comparable to NSV's approach to life sciences investing.
• DCVC (Data Collective): DCVC invests in deep tech and science-driven companies applying breakthroughs in computing, life sciences, and materials. Its emphasis on IP-protected, science-based innovation mirrors NSV's thesis across the IT and life sciences intersection.

Broad incumbents

• Andreessen Horowitz: Andreessen Horowitz is a broad, multi-stage venture capital platform with dedicated life sciences and deep tech strategies. While much larger and more diversified than NSV, its bio/health fund invests in science-based innovation at comparable stages.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/new-science-venture

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments88 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about New Science Ventures